<DOC>
	<DOC>NCT01685424</DOC>
	<brief_summary>This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIAÂ®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).</brief_summary>
	<brief_title>Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>All patients in the MHRA's Full Feature GPRD (FFGPRD) who have at least one electronic outpatient prescription record for etoricoxib issued by a General Practitioner during the period (April 1, 2002 to December 31, 2015) at the date of query execution against the FFGPRD data warehouse. Not registered in a GPRDcontributing practice that had continuously collected data deemed to be 'uptostandard' for research purposes from 1 April 2002 through to 31 December 2015. Never registered as a permanent patient of a General Practitioner in the practice Registration details were not acceptable (i.e. incomplete data or logically implausible dates) Not registered with a General Practitioner for at least 365 days before the date that the patient's first etoricoxib prescription was recorded in the GPRD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Etoricoxib</keyword>
	<keyword>ARCOXIA</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Gout</keyword>
	<keyword>Arthritis</keyword>
</DOC>